Professor, Medicine, University of Minnesota Medical School, Minneapolis
Oncology
Dr. Sharon D. Luikart, MD
|
|
Give Review
Sharon Luikart works in the field of Oncology. She graduated from Duke University School of Medicine. Duke University School of Medicine is one of the top medical schools in the US. Duke University School of Medicine has a rank of 8 in research and a 29 in primary care Sharon D. Luikart, MD is also a published doctor. She has 40 paper published. The most recent paper is: Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
Publications
- Necrosis of uninvolved bone marrow following filgrastim administration in a patient with Burkitt Lymphoma undergoing chemotherapy.
- Mactinin treatment promotes wound-healing-associated inflammation in urokinase knockout mice.
- Mactinin, a fragment of cytoskeletal alpha-actinin, is a novel inducer of heat shock protein (Hsp)-90 mediated monocyte activation.
- Mactinin: a modulator of the monocyte response to inflammation.
- Urokinase is required for the formation of mactinin, an alpha-actinin fragment that promotes monocyte/macrophage maturation.
- HL-60 cells degrade alpha-actinin to produce a fragment that promotes monocyte/macrophage maturation.
- A fragment of alpha-actinin promotes monocyte/macrophage maturation in vitro.
- Renal failure and multiple myeloma.
- The management of multiple myeloma.
- Epithelial carcinoma of the ovary: current strategies.
- Glycosaminoglycan synthesis during differentiation of HL60/HGPRT-Leukemia cells induced by dimethyl sulfoxide and 12-O-tetradecanoylphorbol-13-acetate.
- Influence of collagen substrata on glycosaminoglycan production by B16 melanoma cells.
- Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
- Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
- Effects of HL-60 cell membrane glycosaminoglycans on binding of differentiation-associated receptors.
- Glycosaminoglycan production and distribution in cloned B16 murine melanoma cell lines exhibiting different Lung colony-forming efficiencies.
- Altered glycosaminoglycan production by HL-60 cells treated with 4-methylumbelliferyl-beta-D-xyloside.
- Glycosaminoglycan metabolism of HL-60 cells during differentiation induction by tetradecanoylphorbol-13-acetate.
- Bone marrow matrix modulation of HL-60 phenotype.
- Inability of HL-60 cells induced by phorbol myristate acetate to produce macrophage-associated glycosaminoglycans.
- Effects of colchicine on sulfated glycosaminoglycan production and cell detachment in pre-capillary pulmonary endothelial cells.
- Effects of extracellular matrix on the malignant phenotype.
- Degradation of cartilage proteoglycans by Myeloid leukemia cells.
- BCNU-induced increase in sulfated glycosaminoglycan production by human bone marrow stromal cells.
- High-dose etoposide therapy for extensive small cell lung Cancer: a Cancer and Leukemia Group B Study.
- Serum and urine glycosaminoglycans in Myeloid leukemia and myelodysplasia.
- A heparan sulfate-containing fraction of bone marrow stroma induces maturation of HL-60 cells in vitro.
- The effect of transforming growth factor-beta 1 on glycosaminoglycan production by human marrow cultures.
- Corynebacterium JK: a new pathogen in ventriculostomy infections.
- BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis.
- Bone marrow extracellular matrix induces HL-60 cells to produce an autonomous differentiation factor.
- Epidermolysis bullosa acquisita induced by GM-CSF: a role for eosinophils in treatment-related toxicity.
- Bone marrow matrix promotes differentiation and prolongs the cell cycle of U-937 cells.
- Human bone marrow heparan sulfate induces Leukemia cell differentiation.
- Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung Cancer: a Cancer and Leukemia Group B study (CALGB 8832).
- A phase I/II trial of etoposide and cisplatin in extensive small cell lung Cancer: a Cancer and leukemia group B study.
- Phase I/II trial of etoposide and carboplatin in extensive small-cell lung Cancer. A report from the Cancer and Leukemia Group B.
- Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines.
- Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost Analysis and complications.
Schools
Duke University
Yale University
Conditions Treated
- Anal and Rectal Cancer
- Bladder Cancer
- Chronic Myeloid Leukemia (CML)
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Yale-New Haven Hospital -
Duke University Hospital -
Duke University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Stuart H. Bloom, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph W. Leach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean H. Gesme, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Wilkowske, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michaela L. Tsai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raj S. Kasthuri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dylan M. Zylla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Manion, MD
This Doctor is OpenDoctor Recommended.
|